Literature DB >> 9194984

Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid.

M S Mallett1, R L Hagan, D A Peters.   

Abstract

The stability of ursodiol in an extemporaneously formulated oral liquid was studied. A suspension was prepared by combining the contents of commercially available 300-mg capsules of ursodiol with glycerin, Ora-Plus (Paddock Laboratories), and orange syrup. A second formulation was prepared by combining ursodiol capsules with sterile water for irrigation. The final concentration of ursodiol in each formulation was 25 mg/mL. Six samples of each preparation were stored in 4-oz amber plastic prescription bottles protected from light. Three were stored at 22-23 degrees C and three were refrigerated at 2-6 degrees C. Immediately after preparation and at 7, 15, 30, 45, and 60 days, samples were obtained and frozen until assay by high-performance liquid chromatography. On day 60 the mean percentage of the initial ursodiol concentration remaining was 108.4% for the suspension stored at room temperature and 103.3% for the refrigerated suspension. The ursodiolin-water formulation was not analyzed because of rapid settling of ursodiol. Ursodiol 25 mg/mL in an oral liquid prepared extemporaneously from capsules and sweetened vehicle was stable for 60 days when stored in amber plastic bottles at 22-23 and 2-6 degrees C. Addition of ursodiol powder to water without a suspending agent resulted in a liquid formulation with a high variability in content uniformity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194984     DOI: 10.1093/ajhp/54.12.1401

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  1 in total

1.  Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update.

Authors:  Richard H Parrish; Lisa D Ashworth; Raimar Löbenberg; Sandra Benavides; Jeffrey J Cies; Robert B MacArthur
Journal:  Pharmaceutics       Date:  2022-05-10       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.